Drug Type Therapeutic vaccine |
Synonyms IMA 950, IMA950 |
Target |
Mechanism HLA modulators(Human leukocyte antigen modulators), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 2 | CH | - | - |
Glioblastoma | Phase 2 | - | - | |
Glioblastoma | Phase 2 | - | - | |
Mixed oligoastrocytoma | Phase 1 | US | 03 Apr 2017 | |
Mixed oligoastrocytoma | Phase 1 | US | 03 Apr 2017 | |
Mixed oligoastrocytoma | Phase 1 | US | 03 Apr 2017 | |
Oligodendroglioma | Phase 1 | US | 03 Apr 2017 | |
Oligodendroglioma | Phase 1 | US | 03 Apr 2017 | |
Oligodendroglioma | Phase 1 | US | 03 Apr 2017 | |
WHO Grade II Glioma | Phase 1 | US | 03 Apr 2017 |
Phase 1 | 14 | (IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV) | wlrnddzout(vizmwaqxer) = ywzbqlvtwe bhnfyzaesd (csikpuiwfm, aqwdygiojs - ymiujtuscm) View more | - | 14 Jun 2024 | ||
wlrnddzout(vizmwaqxer) = pangicjdgz bhnfyzaesd (csikpuiwfm, zqnxupljjj - fllxfeoyek) View more |